LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・CureVac NV

CureVac NV

Suletud

5.13 0.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.09

Max

5.15

Põhinäitajad
By Trading Economics
Sissetulek	333M 273M
Müük	493M 494M
P/E Sektori keskmine	7.879 80.03
Aktsiakasum	1.21
Kasumimarginaal	55.32
Töötajad	825
EBITDA	-8.2M -55M

Turustatistika
By TradingEconomics
Turukapital	20M 1.2B
Eelmine avamishind	4.93
Eelmine sulgemishind	5.13

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

3.47 / 3.755 Toetus ja vastupanu

CureVac NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. juuni 2025, 14:20 UTC

Omandamised, ülevõtmised, äriostud

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12. juuni 2025, 13:34 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Võrdlus sarnastega

Hinnamuutus

CureVac NV Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi CureVac NV aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.47 / 3.755Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.